-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article was originally written by Translational Medicine.
Please indicate the source Author: Daisy Introduction: Millions of people in the world are paralyzed due to spinal cord injuries, and there is still no effective treatment.
They may spend their time in wheelchairs at a young age.
the rest of my life
.
Now, for the first time, researchers at Tel Aviv University's Sagol Center for Regenerative Biotechnology have engineered 3D human spinal cord tissue and implanted it in a laboratory model of long-term chronic paralysis.
The model animals undergo a rapid recovery process and eventually they can walk well
.
And studies show that the success rate of restoring walking ability is about 80%
.
The researchers hope to produce individualized spinal cord implants for each paralyzed person, allowing the regeneration of damaged tissue without the risk of rejection
.
It will eventually reach the stage of human clinical trials in the next few years, eventually allowing these patients to get back on their feet and walk again
.
For the first time, researchers at Tel Aviv University's Sagol Center for Regenerative Biotechnology have engineered 3D human spinal cord tissue and implanted it in a laboratory model of long-term chronic paralysis
.
The results were very encouraging: the success rate in restoring walking ability was about 80%
.
Now, the researchers are preparing for the next phase of the study: clinical trials in human patients
.
They hope that within a few years, the engineered tissue will be implanted in paralyzed people, allowing them to stand and walk again
.
The groundbreaking research was led by Professor Tal Dvir's research team from the Sagol Centre for Regenerative Biotechnology, Shmunis School of Biomedical and Cancer Research and Tel Aviv University's Department of Biomedical Engineering
.
The results of this study were published in the journal Advanced Science in an article titled "Regenerating the Injured Spinal Cord at the Chronic Phase by Engineered iPSCs - Derived 3D Neuronal Networks": https://onlinelibrary.
wiley.
com/doi/10.
1002/advs.
202105694 In order to reconnect the injured spinal cord (SC), researchers have proposed a variety of methods, including the transplantation of different types of cells or biomaterials to the injury site during the acute phase
.
Engraftment of Schwann cells, neural stem cells (NSCs) or neural progenitor cells (NPCs), or mesenchymal stem cells has been investigated as a potential treatment for SC injury
.
However, two problems may jeopardize the success of the treatment, namely, an immune response to allogeneic or allogeneic cells that may promote cellular rejection, and the engraftment of free cells that fail to organize into a functional network
.
To overcome the risk of rejection, induced pluripotent stem cells (iPSCs) can be used
.
In this approach, the patient's somatic cells are reprogrammed to become pluripotent and then differentiate into the desired cell lineage
.
The most common strategy in regeneration of damaged SCs is not to apply undifferentiated cells directly, but to transplant various iPSC-derived cell lines
.
Professor Dvir said: "Our technique is based on taking a small slice from a patient's abdominal fat tissue
.
This tissue, like all tissues in our body, is made up of cells and an extracellular matrix, including substances like collagen and sugars
.
After separating the cells from the extracellular matrix, we use genetic engineering to reprogram the cells back to a state similar to embryonic stem cells—cells that can become any type of cell in the body
.
From the extracellular matrix, we produced a personalized hydrogel that did not elicit an immune response or rejection upon implantation
.
We then encapsulated the stem cells in a hydrogel, and in a process that mimics embryonic development of the spinal cord, we transformed the cells into 3D implants containing neuronal networks of motor neurons
.
MRIs of injured spinal cords with and without treatment Spinal cord treatment images swipe left and right to see more Human spinal cord implants were then implanted into laboratory models, which were divided into two groups: One was recently paralyzed ( Acute model), and another group with prolonged paralysis (equivalent to one year in humans) (chronic model)
.
After implantation, 100% of the acute paralysis laboratory model and 80% of the chronic paralysis laboratory model recovered.
Professor Dvir said: "The model animals underwent a rapid recovery process, and at the end they were able to walk well
.
This is the first time in the world that engineered human tissue has been implanted in an animal model to restore long-term chronic paralysis - the most relevant model for paralysis treatment in humans .
Millions of people around the world are paralyzed by spinal cord injuries, and there is still no effective treatment .
People injured at an early age are destined to spend the rest of their lives in wheelchairs, bearing all the social, economic and health costs of paralysis .
Our goal is to produce individualized spinal cord implants for every paralyzed person, allowing the regeneration of damaged tissue without the risk of rejection.
"Based on revolutionary organ engineering techniques developed in Professor Dvir's laboratory, he and industry partners founded Matricelf (matricelf.
com) in 2019.
The
company applies Professor Dvir's method to spinal cord implants, with the goal of giving paralyzed patients access to Commercializing the treatment
.
Neural Networks Image Professor Dvir, who heads the Sagol Centre for Regenerative Biotechnology, concluded: "We hope to reach the stage of human clinical trials in the next few years and eventually get these patients back on their feet
.
The company's preclinical program has been discussed with the FDA
.
Since we've come up with an advanced technology in regenerative medicine and there are currently no other alternatives for paralyzed patients, we have every reason to expect our technology to be approved relatively quickly
.
"Reference: https://medicalxpress.
com/news/2022-02-world-first-human-spinal-cord-implants.
html Note: This article is intended to introduce medical research progress and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
Please indicate the source Author: Daisy Introduction: Millions of people in the world are paralyzed due to spinal cord injuries, and there is still no effective treatment.
They may spend their time in wheelchairs at a young age.
the rest of my life
.
Now, for the first time, researchers at Tel Aviv University's Sagol Center for Regenerative Biotechnology have engineered 3D human spinal cord tissue and implanted it in a laboratory model of long-term chronic paralysis.
The model animals undergo a rapid recovery process and eventually they can walk well
.
And studies show that the success rate of restoring walking ability is about 80%
.
The researchers hope to produce individualized spinal cord implants for each paralyzed person, allowing the regeneration of damaged tissue without the risk of rejection
.
It will eventually reach the stage of human clinical trials in the next few years, eventually allowing these patients to get back on their feet and walk again
.
For the first time, researchers at Tel Aviv University's Sagol Center for Regenerative Biotechnology have engineered 3D human spinal cord tissue and implanted it in a laboratory model of long-term chronic paralysis
.
The results were very encouraging: the success rate in restoring walking ability was about 80%
.
Now, the researchers are preparing for the next phase of the study: clinical trials in human patients
.
They hope that within a few years, the engineered tissue will be implanted in paralyzed people, allowing them to stand and walk again
.
The groundbreaking research was led by Professor Tal Dvir's research team from the Sagol Centre for Regenerative Biotechnology, Shmunis School of Biomedical and Cancer Research and Tel Aviv University's Department of Biomedical Engineering
.
The results of this study were published in the journal Advanced Science in an article titled "Regenerating the Injured Spinal Cord at the Chronic Phase by Engineered iPSCs - Derived 3D Neuronal Networks": https://onlinelibrary.
wiley.
com/doi/10.
1002/advs.
202105694 In order to reconnect the injured spinal cord (SC), researchers have proposed a variety of methods, including the transplantation of different types of cells or biomaterials to the injury site during the acute phase
.
Engraftment of Schwann cells, neural stem cells (NSCs) or neural progenitor cells (NPCs), or mesenchymal stem cells has been investigated as a potential treatment for SC injury
.
However, two problems may jeopardize the success of the treatment, namely, an immune response to allogeneic or allogeneic cells that may promote cellular rejection, and the engraftment of free cells that fail to organize into a functional network
.
To overcome the risk of rejection, induced pluripotent stem cells (iPSCs) can be used
.
In this approach, the patient's somatic cells are reprogrammed to become pluripotent and then differentiate into the desired cell lineage
.
The most common strategy in regeneration of damaged SCs is not to apply undifferentiated cells directly, but to transplant various iPSC-derived cell lines
.
Professor Dvir said: "Our technique is based on taking a small slice from a patient's abdominal fat tissue
.
This tissue, like all tissues in our body, is made up of cells and an extracellular matrix, including substances like collagen and sugars
.
After separating the cells from the extracellular matrix, we use genetic engineering to reprogram the cells back to a state similar to embryonic stem cells—cells that can become any type of cell in the body
.
From the extracellular matrix, we produced a personalized hydrogel that did not elicit an immune response or rejection upon implantation
.
We then encapsulated the stem cells in a hydrogel, and in a process that mimics embryonic development of the spinal cord, we transformed the cells into 3D implants containing neuronal networks of motor neurons
.
MRIs of injured spinal cords with and without treatment Spinal cord treatment images swipe left and right to see more Human spinal cord implants were then implanted into laboratory models, which were divided into two groups: One was recently paralyzed ( Acute model), and another group with prolonged paralysis (equivalent to one year in humans) (chronic model)
.
After implantation, 100% of the acute paralysis laboratory model and 80% of the chronic paralysis laboratory model recovered.
Professor Dvir said: "The model animals underwent a rapid recovery process, and at the end they were able to walk well
.
This is the first time in the world that engineered human tissue has been implanted in an animal model to restore long-term chronic paralysis - the most relevant model for paralysis treatment in humans .
Millions of people around the world are paralyzed by spinal cord injuries, and there is still no effective treatment .
People injured at an early age are destined to spend the rest of their lives in wheelchairs, bearing all the social, economic and health costs of paralysis .
Our goal is to produce individualized spinal cord implants for every paralyzed person, allowing the regeneration of damaged tissue without the risk of rejection.
"Based on revolutionary organ engineering techniques developed in Professor Dvir's laboratory, he and industry partners founded Matricelf (matricelf.
com) in 2019.
The
company applies Professor Dvir's method to spinal cord implants, with the goal of giving paralyzed patients access to Commercializing the treatment
.
Neural Networks Image Professor Dvir, who heads the Sagol Centre for Regenerative Biotechnology, concluded: "We hope to reach the stage of human clinical trials in the next few years and eventually get these patients back on their feet
.
The company's preclinical program has been discussed with the FDA
.
Since we've come up with an advanced technology in regenerative medicine and there are currently no other alternatives for paralyzed patients, we have every reason to expect our technology to be approved relatively quickly
.
"Reference: https://medicalxpress.
com/news/2022-02-world-first-human-spinal-cord-implants.
html Note: This article is intended to introduce medical research progress and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event The first Yangtze River Delta single-cell omics technology application forum "Drug Precision" series of live broadcasts: the second phase of MRD detection and Car-T cell therapy development popular articles Organoid research [year-end inventory] must-see in the field of organoids in 2021 Essential Research Content Medical Research [Cell Sub-Journal] Optimization Technology! Restore human cells to stem cell state! Cancer Research [Science Sub-Journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Genetic Testing【Science Sub-Journal】A previously unknown gene mutation, BAG5, can cause incurable heart disease cancer research 【Science Sub-Journal】“Pseudogene” carcinogenic? Research identifies a new pathway leading to liver cancer -- pseudogene demethylation, which could help develop new treatments! New research shows how to test the effectiveness of anti-cancer drugs
